SCHEMBL178439

SCHEMBL178439

CCc1ccc(C(N)=O)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.64
SMN1; SMN2 Q16637 2/20 0.61
PLK1 P53350 1/20 0.57
PLA2G10 O15496 1/20 0.57
PLA2G2A P14555 1/20 0.57
PARP10 Q53GL7 5/20 0.55
PARP4 Q9UKK3 2/20 0.50
PARP1 P09874 2/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
PARP2 Q9UGN5 1/20 0.50
MAPT P10636 2/20 0.49
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
TDP1 Q9NUW8 2/20 0.48
CYP17A1 P05093 1/20 0.48
PLAU P00749 1/20 0.48
KMT2A Q03164 2/20 0.48
PARP15 Q460N3 1/20 0.48
PARP14 Q460N5 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10243616 0.94 CYP17A1 (0.58) ALDH1A1SMN1; SMN2PLK1PLA2G10PLA2G2A
SCHEMBL4520699 0.94 CYP17A1 (0.58) ALDH1A1SMN1; SMN2PLK1PLA2G10PLA2G2A
Benzamide SCHEMBL27520826 0.89 L3MBTL1 (0.67) ALDH1A1SMN1; SMN2PLK1PLA2G10PLA2G2A
SCHEMBL21628385 0.88 PARP10 (0.70) ALDH1A1SMN1; SMN2PARP10PARP4PARP1
Trifluoroacetic Acid SCHEMBL7850274 0.87 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2PLK1PLA2G10PLA2G2A
SCHEMBL17688293 0.82 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2PLK1PLA2G10PLA2G2A
Acetamide SCHEMBL27414047 0.82 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2PLK1CA2LMNA
SCHEMBL2464783 0.82 PLK1 (0.60) ALDH1A1PLK1PLA2G10PLA2G2APARP10
SCHEMBL10788805 0.82 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2PLK1CA2MAPT
SCHEMBL24890468 0.81 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2PLK1MAPTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 744 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119371298-A Method for efficiently synthesizing indenone compound 南阳师范学院 2025-01-28 CN claimed
CN-115044275-A Pipeline protection coating and production process thereof 山东佰盛能源科技有限公司 2022-09-13 CN claimed
EP-3846691-A2 SYSTEM FOR DETECTION OF VOLATILE ORGANIC COMPOUNDS (VOC) IN EXHALED BREATH FOR HEALTH MONITORING Kozhnosys Private Limited (IN) 2021-07-14 EP claimed
US-20210186367-A1 SYSTEM FOR DETECTION OF VOLATILE ORGANIC COMPOUNDS (VOC) IN EXHALED BREATH FOR HEALTH MONITORING KOZHNOSYS PRIVATE LIMITED (IN) 2021-06-24 US claimed
EP-3233836-B1 INDAZOLE SULFONAMIDE DERIVATIVES AS INVERSE AGONISTS OF RETINOID-RELATED ORPHAN RECEPTOR GAMMA (ROR GAMMA (T)) GALDERMA RES & DEV (FR) 2019-01-30 EP claimed
EP-1773768-B1 PYRROLE DERIVATIVES AS PHARMACEUTICAL AGENTS EXELIXIS INC (US) 2018-08-22 EP claimed
CN-107108971-A Improved rubber composition and use thereof 株式会社普利司通 2017-08-29 CN claimed
CN-103096893-B Glycine transporter-1 inhibitor, Its Preparation Method And Use ALBANY MOLECULAR RESEARCH, INC. (US) 2016-05-04 CN claimed
US-9198426-B2 Use of 5 pyridin-4-yl-1,3-thiazoles for controlling phytopathogenic fungi BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-01 US claimed
EP-1888596-B1 SUBSTITUTED SPIRO COMPOUNDS AND THEIR USE FOR PRODUCING PAIN-RELIEF MEDICAMENTS GRUENENTHAL GMBH (DE) 2014-10-22 EP claimed
EP-1325006-A2 HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABA A? RECEPTOR NEUROGEN CORPORATION (US) 2003-07-09 EP claimed
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor PFIZER INC 2003-06-05 US claimed
US-6380247-B2 A WOOD PRESERVATIVE; POTENTIATION WHEN MIXED WITH AT LEAST ONE OF 3-BROMO-2,3-DIIODO-2-PROPENYL-ETHYLCARBAMATE, 3-IODO-2-PROPYNYLBUTYL-CARBAMATE AND 4-CHLOROPHENYL-3-IODOPROPARGYLFORMAL; MICROBIOCIDES SANKYO COMPANY, LIMITED (JP) 2002-04-30 US claimed
WO-2002028353-A2 PHOSPHATE TRANSPORT INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2002-04-11 WO claimed
WO-2002012442-A2 HETEROCYCLIC COMPOUNDS AS LIGANDS OF THE GABAA RECEPTOR NEUROGEN CORPORATION (US) 2002-02-14 WO claimed
EP-1150565-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION bioscience AG (DE) 2001-11-07 EP claimed
EP-1126833-A2 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2001-08-29 EP claimed
WO-2000045635-A1 THIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF LION BIOSCIENCE AG (DE) 2000-08-10 WO claimed
CN-1255124-A Substituted isoquinoline derivatives and their use as anticonulsants SMITHKLINE BEECHAM PLC (GB) 2000-05-31 CN claimed
WO-2000025768-A1 OXADIAZOLE, THIADIAZOLE AND TRIAZOLE DERIVATIVES AND COMBINATORIAL LIBRARIES THEREOF TREGA BIOSCIENCES, INC. (US) 2000-05-11 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 ALDH1A1 1197/4885SMN1; SMN2 3794/4885PLK1 4619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.